替罗非班在症状性颅内动脉粥样硬化性狭窄支架置入前应用的有效性与安全性:一项随机临床试验
这项在中国10个中心开展的前瞻性、多中心、开放标签随机临床试验,于2020年9月9日至2022年2月18日纳入200例拟行支架血管成形术的症状性重度颅内动脉粥样硬化性狭窄患者,1:1随机接受支架置入前静脉替罗非班或不接受。结果显示替罗非班组急性支架内血栓形成发生率低于对照组(4.0% vs 14.0%;调整OR 0.25;95%CI 0.08-0.82;p=0.02),围手术期缺血性卒中及症状性颅内出血发生率两组无显著差异。
要点
- 支架置入前静脉替罗非班可降低症状性重度ICAS患者急性支架内血栓形成发生率(4.0% vs 14.0%;调整OR 0.25;95%CI 0.08-0.82;p=0.02)。
- 围手术期缺血性卒中发生率两组无显著差异(7.0% vs 8.0%;p=0.98)。
- 症状性颅内出血发生率两组无显著差异。
核心结论
- 本研究提示,支架置入前辅助静脉替罗非班可降低症状性重度ICAS患者支架血管成形术中的急性支架内血栓形成风险。
- 本研究提供II级证据:对症状性重度ICAS患者,替罗非班预处理可降低急性支架内血栓形成发生率;因两组受累动脉分布不均衡,证据等级定为II级。
研究设计与样本
- 前瞻性、多中心、开放标签、随机临床试验,于2020年9月9日至2022年2月18日在中国10个医疗中心开展。
- 纳入拟行支架血管成形术的症状性重度ICAS患者,按1:1比例随机分配至支架置入前静脉替罗非班组或不接受替罗非班的对照组。
- 共200例参与者纳入分析(男性122例[61.0%];中位[四分位距]年龄57[52-66]岁),替罗非班组100例,对照组100例。
- 主要结局包括支架置入后30分钟内急性支架内血栓形成发生率、围手术期新发缺血性卒中及症状性颅内出血;采用逻辑回归分析获得比值比及95%置信区间。
主要发现
- 替罗非班组急性支架内血栓形成发生率低于对照组(4.0% vs 14.0%;调整OR 0.25;95%CI 0.08-0.82;p=0.02)。
- 围手术期缺血性卒中发生率两组无显著差异(7.0% vs 8.0%;p=0.98)。
- 症状性颅内出血发生率两组无显著差异。
临床怎么用
- 本研究提示,对症状性重度ICAS行支架血管成形术的患者,支架置入前辅助静脉替罗非班可降低急性支架内血栓形成风险。
- 研究提供II级证据支持替罗非班预处理降低急性支架内血栓形成发生率,但因两组受累动脉分布不均衡,证据等级定为II级。
局限性
- 本研究为开放标签设计。
- 两组受累动脉分布不均衡,因此证据等级定为II级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Acute stent thrombosis (AST) is not uncommon and even catastrophic during intracranial stenting angioplasty in patients with symptomatic high-grade intracranial atherosclerotic stenosis (ICAS). The purpose of this study was to investigate whether adjuvant intravenous tirofiban before stenting could reduce the risk of AST and periprocedural ischemic stroke in patients receiving stent angioplasty for symptomatic ICAS. METHODS: A prospective, multicenter, open-label, randomized clinical trial was conducted from September 9, 2020, to February 18, 2022, at 10 medical centers in China. Patients intended to receive stent angioplasty for symptomatic high-grade ICAS were enrolled and randomly assigned to receive intravenous tirofiban or not before stenting in a 1:1 ratio. The primary outcomes included the incidence of AST within 30 minutes after stenting, periprocedural new-onset ischemic stroke, and symptomatic intracranial hemorrhage. The outcomes were analyzed using logistic regression analysis to obtain an odds ratio and 95% confidence interval. RESULTS: A total of 200 participants (122 men [61.0%]; median [interquartile ranges] age, 57 [52-66] years) were included in the analysis, with 100 participants randomly assigned to the tirofiban group and 100 participants to the control (no tirofiban) group. The AST incidence was lower in the tirofiban group than that in the control group (4.0% vs 14.0%; adjusted odds ratio, 0.25; 95% CI 0.08-0.82; p = 0.02). No significant difference was observed in the incidence of periprocedural ischemic stroke (7.0% vs 8.0%; p = 0.98) or symptomatic intracranial hemorrhage between the 2 groups. DISCUSSION: This study suggests that adjuvant intravenous tirofiban before stenting could lower the risk of AST during stent angioplasty in patients with symptomatic high-grade ICAS. TRIAL REGISTRATION INFORMATION: URL: chictr.org.cn; Unique identifier: ChiCTR2000031935. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with symptomatic high-grade ICAS, pretreatment with tirofiban decreases the incidence of acute stent thrombosis. This study is Class II due to the unequal distribution of involved arteries between the 2 groups.
引用
- Zhang J, Huang X, Wang G, et al. Efficacy and Safety of Tirofiban Before Stenting for Symptomatic Intracranial Atherosclerotic Stenosis: A Randomized Clinical Trial. Neurology. 2024. PMID: 38489544. doi:10.1212/WNL.0000000000209217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。